文献速递泌尿男性生殖肿瘤

晚期肾细胞癌治疗中肿瘤与外周生物标志物的整合分析

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
PubMed 文献 · Cancer Discov · 2024-01-01

III期JAVELIN Renal 101试验(N=886)显示,一线阿维鲁单抗+阿昔替尼(A+Ax)较舒尼替尼延长晚期肾细胞癌患者的无进展生存期(PFS)。本文对纵向血样和基线肿瘤组织进行整合分析,发现PFS在舒尼替尼组与淋巴细胞水平升高相关,在A+Ax组与固有免疫亚群丰富相关;A+Ax诱导更强的T细胞库调节且T细胞数量变化更小;携带≥2个(共10个已鉴定的PFS相关基因)突变的双突变肿瘤患者具有独特的循环和肿瘤浸润免疫特征。

要点

  • A+Ax较舒尼替尼延长晚期肾细胞癌患者的PFS(N=886)。
  • 舒尼替尼组PFS与淋巴细胞水平升高相关,A+Ax组与固有免疫亚群丰富相关。
  • A+Ax诱导更强的T细胞库调节且T细胞数量变化小于舒尼替尼。

核心结论

  • A+Ax与舒尼替尼通过不同的免疫调节机制发挥作用,肿瘤分子亚型可影响免疫细胞浸润与相互作用。

研究设计与样本

  • III期JAVELIN Renal 101试验(N=886)的整合分析,对纵向血样和基线肿瘤组织进行检测。

主要发现

  • PFS在舒尼替尼组与淋巴细胞水平升高相关,在A+Ax组与固有免疫亚群丰富相关。
  • A+Ax较舒尼替尼引起更强的T细胞库调节和更小的T细胞数量变化。
  • 在A+Ax组,携带10个已鉴定PFS相关基因中≥2个突变的双突变肿瘤患者,其循环和肿瘤浸润免疫特征与野生型或单突变肿瘤患者不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax) versus sunitinib. We report novel findings from integrated analyses of longitudinal blood samples and baseline tumor tissue. PFS was associated with elevated lymphocyte levels in the sunitinib arm and an abundance of innate immune subsets in the A+Ax arm. Treatment with A+Ax led to greater T-cell repertoire modulation and less change in T-cell numbers versus sunitinib. In the A+Ax arm, patients with tumors harboring mutations in ≥2 of 10 previously identified PFS-associated genes (double mutants) had distinct circulating and tumor-infiltrating immunologic profiles versus those with wild-type or single-mutant tumors, suggesting a role for non-T-cell-mediated and non-natural killer cell-mediated mechanisms in double-mutant tumors. We provide evidence for different immunomodulatory mechanisms based on treatment (A+Ax vs. sunitinib) and tumor molecular subtypes. SIGNIFICANCE: Our findings provide novel insights into the different immunomodulatory mechanisms governing responses in patients treated with avelumab (PD-L1 inhibitor) + axitinib or sunitinib (both VEGF inhibitors), highlighting the contribution of tumor biology to the complexity of the roles and interactions of infiltrating immune cells in response to these treatment regimens. This article is featured in Selected Articles from This Issue, p. 384.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Choueiri TK, Donahue AC, Braun DA, et al. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discov. 2024. PMID: 38385846. doi:10.1158/2159-8290.CD-23-0680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。